Cargando…

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease

SIMPLE SUMMARY: In patients with inflammatory bowel disease, chronic inflammation is a risk factor for the development of digestive and nondigestive cancers. The treatment, as in patients without inflammatory bowel disease, is a combination of chemotherapy and targeted treatments, such as bevacizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-Gómez, Ruth Gabriela, Grecea, Miruna, Gallois, Claire, Boige, Valérie, Pautier, Patricia, Pistilli, Barbara, Planchard, David, Malka, David, Ducreux, Michel, Mir, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220809/ https://www.ncbi.nlm.nih.gov/pubmed/35740579 http://dx.doi.org/10.3390/cancers14122914

Ejemplares similares

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer
por: Chaput, N, et al.
Publicado: (2013)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up
por: Veron, Lucie, et al.
Publicado: (2021)

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
por: de Rauglaudre, Bernadette, et al.
Publicado: (2022)

An update on treatment options for pancreatic adenocarcinoma
por: Lambert, Aurélien, et al.
Publicado: (2019)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2022)

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
por: Remon, Jordi, et al.
Publicado: (2019)

Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases
por: Gelli, Maximiliano, et al.
Publicado: (2023)

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer
por: Ostby, Stuart A., et al.
Publicado: (2020)

Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis
por: Vergara, John Paulo, et al.
Publicado: (2019)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial
por: Boige, V, et al.
Publicado: (2007)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
por: Ducreux, Michel
Publicado: (2009)

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review
por: Poku, Edith, et al.
Publicado: (2014)

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
por: Kudo, Masatoshi, et al.
Publicado: (2023)

Intravitreal bevacizumab: an analysis of the evidence
por: Smit, Derrick P, et al.
Publicado: (2007)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
por: Mayenga, Marie, et al.
Publicado: (2023)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
por: Sullivan, Ivana, et al.
Publicado: (2016)

Oncogene addiction and immune escape: friends or foes?
por: Abdayem, Pamela, et al.
Publicado: (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
por: Abdayem, Pamela, et al.
Publicado: (2020)

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
por: Abdayem, Pamela, et al.
Publicado: (2021)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
por: Matte, Paul, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qao3dd0rf8uobuc2r7u3m03kan